Human ACAT inhibitory effects of shikonin derivatives from Lithospermum erythrorhizon

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 4, 2007, Pages 1112-1116

  An, Sojin ^a,c   Park, Yong Dae ^a,b   Paik, Young Ki ^c   Jeong, Tae Sook ^a   Lee, Woo Song ^a,b  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

ACAT inhibitor; Shikonin derivatives

Indexed keywords

(3 HYDROXYISOVALERYL)SHIKONIN; 1,4 NAPHTHOQUINONE DERIVATIVE; ACETYLSHIKONIN; CHLOROFORM; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; ISOBUTYRYLSHIKONIN; LITHOSPERMUM EXTRACT; SHIKONIN; SHIKONIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG ACTIVITY; DRUG HYDROLYSIS; DRUG ISOLATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; LITHOSPERMUM; LITHOSPERMUM ERYTHRORHIZON; NONHUMAN; PLANT ROOT;

CHLOROFORM; ENZYME INHIBITORS; HUMANS; ISOENZYMES; LITHOSPERMUM; MICROSCOPY, FLUORESCENCE; NAPHTHOQUINONES; PLANT ROOTS; SOLVENTS; STEROL O-ACYLTRANSFERASE; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

LITHOSPERMUM ERYTHRORHIZON;

EID: 33846568869     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.11.024     Document Type: Article

References (24)

1. Largis E.E., Wang V.H., DeVries V.G., and Schaffer S.A. J. Lipid Res. 30 (1989) 681
2. Chang T.Y., Chang C.C., and Cheng D. Annu. Rev. Biochem. 66 (1997) 613
3. Chang T.Y., Chang C.C., Lin S., Yu C., Li B.L., and Miyazaki A. Curr. Opin. Lipidol 12 (2001) 289
4. Bocan T.M., Mueller S.B., Hendorf P.D., Brown E.Q., Mazur M.J., and Black A.E. Atherosclerosis 99 (1993) 175
5. Kusunoki J., Hansoty D.K., Aragane K., Fallon J.T., Badimon J.J., and Fisher E.A. Circulation 103 (2001) 2604
6. Delsing D.J., Offerman E.H., Duyvenvoorde W.V., Boom H., Wit E.C., Gijbels M.J., Laarse A., Jukema J.W., Havekes L.M., and Princen H.M. Circulation 103 (2001) 1778
7. For recent reviews of ACAT inhibitor, see. Giovannoni M.P., Dal Piaz V., Vergelli C., and Barlocco D. Mini-Rev. Med. Chem. 3 (2003) 576
8. Sliskovic D.R., Picard J.A., and Krause B.R. Prog. Med. Chem. 39 (2002) 121
9. Nissen S.E., Tuzcu E.M., Brewer H.B., Sipahi I., Nicholls S.J., Ganz P., Schoenhagen P., Waters D.D., Pepine C.J., Crowe T.D., Davidson M.H., Deanfield J.E., Wisniewski L.M., Hanyok J.J., and Kassalow L.M. N. Engl. J. Med. 354 (2006) 1253
10. Lee W.S., Lee D.W., Baek Y.I., An S.J., Cho K.H., Choi Y.K., Kim H.J., Park H.Y., Bae K.H., and Jeong T.S. Bioorg. Med. Chem. Lett. 14 (2004) 3109
11. 2O (9:1) to yield 2 (30 mg). Fraction 4 was purified by chromatography on silica gel (230-400 mesh, Merck, Ø50 × 150 mm), eluted with n-hexane/EtOAc (5:1) to yield 3 (70 mg).
12. 3, 300 MHz): δ 176.9, 175.4, 171.6, 168.5, 167.9, 147.4, 136.3, 133.2, 133.0, 131.3, 117.6, 111.7, 111.5, 69.7, 69.0, 46.4, 32.8, 29.2, 29.0, 25.7, 17.9.
13. Papageorgiou V.P., Assimopoulou A.N., Couladouros E.A., David H., and Nicolaou K.C. Angew. Chem. Int. Ed. 38 (1999) 270
14. Cho K.H., An S., Lee W.S., Paik Y.K., Kim Y.K., and Jeong T.S. Biochem. Biophys. Res. Commun. 309 (2003) 864
15. 15. Briefly, Flp-In AC-29 cells containing five copies of integrated FRT sequence were generated by transfection of pFRT/lacZeo into AC-29 cells. FRT site-integrated clones were selected by 100 μg/mL zeocin (Invitrogen) for 1 week. Several colonies were picked and maintained in F-12 medium supplemented with 10% fetal bovine serum (FBS) and 100 μg/mL zeocin. The presence and number of FRT-site were verified by β-galactosidase assay and Southern blot analysis, respectively. To construct stable cell lines expressing hACAT-1 or hACAT-2, Flp-In AC-29 cells were plated on 60-mm dishes and transfected with 1.8 μg of the Flp-In recombinase-encoding pOG44 vector and either 0.2 μg of pcDNA5/FRT-hACAT-1 or pcDNA5/FRT-hACAT-2. After 2 days, we proceeded to select the single colony with 500 μg/mL hygromycin (Invitrogen) for 2 weeks. Colonies were picked up, expanded, and assayed for expression of hACAT-1 or -2. Established cell lines were maintained in F-12/10% FBS containing 100 μg/mL hygromycin.
16. 15 a total of 30,000 cells per well were plated on 96-well culture plates and allowed to recover overnight. Assays were done with cells at least 80% confluent. Cells were incubated in Ham's F-12 medium supplemented with 1% Eagle's vitamins and 10% heat-inactivated FBS containing 5 μg/mL NBD-cholesterol as methyl-β-cyclodextrin complex with or without ACAT inhibitor for 9 h. NBD-cholesterol was added from a 5-mg/mL stock solution in methanol, and methanol concentrations in the medium did not exceed 0.1%. Flp-In AC-29 cells incubated with NBD-cholesterol were used to determine background fluorescence attributable to free NBD-cholesterol. After incubation, the medium was removed, and the cells were washed two times with cold balanced salt solution (BSS, Invitrogen). The fluorescent intensities of 96-well culture plates were read from the top using VICTOR3 fluorescent plate reader (Perkin-Elmer) equipped with 485 nm excitation and 535 nm emission filters. After measurement, cellular protein was digested through incubation with 25 μL of 0.4 N NaOH for 2 h. The fluorescent intensity was normalized by cellular protein content and calculated by subtracting the background fluorescent intensity from the total fluorescent intensity.
17. 20 100 μM of MβCD was dissolved in 10 mL F-12 medium, and 6 μM NBD-cholesterol, and 10 μg/mL BSA were added to this solution with vigorous vortex. The dispersion was sonicated at room temperature for 5 min using a Fisher model 60 sonic dismembrator at setting 5. The solution was filtered with 0.45 μm membrane filter and kept in a glass tube under argon at 4 °C for up to a week.
18. Lada A.T., Davis M., Kent C., Chapman J., Tomoda H., Ōmura S., and Rudel L.L. J. Lipid Res. 45 (2004) 378
19. Guo Z.-Y., Lin S., Heinen J.A., Chang C.C.Y., and Chang T.-Y. J. Biol. Chem 280 (2005) 37814
20. Lin S., Lu X., Chang C.C.Y., and Chang T.-Y. Mol. Biol. Cell 14 (2003) 2447
21. An S., Cho K.H., Lee W.S., Lee J.O., Paik Y.K., and Jeong T.S. FEBS Lett. 580 (2006) 2741
22. Ikenoya, M.; Yoshinaka, Y.; Kobayashi, H.; Kawamine, K.; Shibuya, K.; Sato, F.; Sawanobori, K.; Watanabe, T.; Miyazaki, A. Atherosclerosis. 2006, July 1; (Epub. ahead of print).
23. Rudel L.L., Lee R.G., and Cockman T.L. Curr. Opin. Lipidol. 12 (2001) 121
24. Li Y., Ge M., Ciani L., Kuriakose G., Westover E.J., Dura M., Covey D.F., Freed J.H., Maxfield F.R., Lytton J., and Tabas I. J. Biol. Chem. 279 (2004) 37030